Although U-CLL shows a more robust constitutive BcR pathway activation and a better responsiveness to BcR engagement, our data suggest that the BcR pathway is also a therapeutic target in IgG CLL. Here, BCR is linked to B-cell chronic lymphocytic leukemia.